Reduced expression of DENND2D through promoter hypermethylation is an adverse prognostic factor in squamous cell carcinoma of the esophagus

Hibino,Soki; Kanda,Mitsuro; Oya,Hisaharu; Takami,Hideki; Shimizu,Dai; Nomoto,Shuji; Hishida,Mitsuhiro; Niwa,Yukiko; Koike,Masahiko; Yamada,Suguru; Nishikawa,Yoko; Asai,Mikako; Nakayama,Goro; Fujii,Tsutomu; Sugimoto,Hiroyuki; Fujiwara,Michitaka; Kodera,Yasuhiro

doi:10.3892/or.2013.2901

Reduced expression of DENND2D through promoter hypermethylation is an adverse prognostic factor in squamous cell carcinoma of the esophagus

Authors:
- Soki Hibino
- Mitsuro Kanda
- Hisaharu Oya
- Hideki Takami
- Dai Shimizu
- Shuji Nomoto
- Mitsuhiro Hishida
- Yukiko Niwa
- Masahiko Koike
- Suguru Yamada
- Yoko Nishikawa
- Mikako Asai
- Goro Nakayama
- Tsutomu Fujii
- Hiroyuki Sugimoto
- Michitaka Fujiwara
- Yasuhiro Kodera
View Affiliations

Affiliations: Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan
Published online on: December 5, 2013 https://doi.org/10.3892/or.2013.2901
Pages: 693-700

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Esophageal cancer ranks sixth in cancer mortality worldwide and patients with esophageal squamous cell carcinoma (ESCC) have a poor prognosis with a 5-year survival rate of less than 10%. Elucidation of the mechanisms of carcinogenesis and tumor progression in esophageal cancer is urgently required to develop targets for therapy and prognostic biomarkers. In the present study, the expression and regulatory mechanism of the differentially expressed in normal and neoplastic cells domain containing 2D (DENND2D), which is a regulator of Rab GTPases, were investigated to explore its potential as a tumor suppressor gene for ESCC. The level of DENND2D mRNA expression in ESCC cell lines and surgical specimens was determined using a quantitative real-time reverse transcription-polymerase chain reaction assay, and the relationship between the expression levels of DENND2D mRNA and clinicopathological factors was evaluated. The expression and distribution of DENND2D were determined using immunohistochemistry. DNA methylation analysis was performed to determine the regulatory mechanism of DENND2D expression in ESCC. The level of DENND2D mRNA expression was reduced in 8/9 ESCC cell lines and in 59/65 surgical specimens, and the mean expression levels were significantly lower in cancerous tissues compared to corresponding normal tissues (p<0.001). The expression pattern of DENND2D protein and mRNA was consistent. Downregulation of DENND2D mRNA in ESCC tissues was identified as an independent prognostic factor in multivariate analysis (hazard ratio, 2.194; p=0.039). The DENND2D promoter was methylated in 5/9 ESCC cell lines, and DNA demethylation reactivated DENND2D mRNA expression. Hypermethylation of DENND2D was frequently detected in ESCC tissues (64.6%) and was significantly associated with downregulation of DENND2D mRNA expression (P=0.008). Taken together, our data suggest that DENND2D is a candidate tumor suppressor gene that was inactivated by promoter hypermethylation in patients with ESCC and may serve as a novel biomarker of ESCC.

View Figures

View References

1	Ferlay J, Shin H, Bray F, Forman D, Mathers C and Parkin D: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
3	Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar
4	Kanda M, Nomoto S, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S and Nakao A: Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters. J Surg Oncol. 98:190–196. 2008. View Article : Google Scholar : PubMed/NCBI
5	Kanda M, Nomoto S, Okamura Y, Hayashi M, Hishida M, Fujii T, Nishikawa Y, Sugimoto H, Takeda S and Nakao A: Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. Mol Carcinog. 50:571–579. 2011. View Article : Google Scholar : PubMed/NCBI
6	Kanda M, Nomoto S, Okamura Y, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S and Nakao A: Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int J Oncol. 35:477–483. 2009.
7	Wang YN, Yamaguchi H, Hsu JM and Hung MC: Nuclear trafficking of the epidermal growth factor receptor family membrane proteins. Oncogene. 29:3997–4006. 2010. View Article : Google Scholar : PubMed/NCBI
8	Casas A, Di Venosa G, Hasan T and Al Batlle: Mechanisms of resistance to photodynamic therapy. Curr Med Chem. 18:2486–2515. 2011. View Article : Google Scholar : PubMed/NCBI
9	Stenmark H: Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol. 10:513–525. 2009. View Article : Google Scholar : PubMed/NCBI
10	Pawson T and Nash P: Assembly of cell regulatory systems through protein interaction domains. Science. 300:445–452. 2003. View Article : Google Scholar : PubMed/NCBI
11	Marat AL and McPherson PS: The connecdenn family, Rab35 guanine nucleotide exchange factors interfacing with the clathrin machinery. J Biol Chem. 285:10627–10637. 2010. View Article : Google Scholar : PubMed/NCBI
12	Sato M, Sato K, Liou W, Pant S, Harada A and Grant BD: Regulation of endocytic recycling by C. elegans Rab35 and its regulator RME-4, a coated-pit protein. EMBO J. 27:1183–1196. 2008.
13	Levivier E, Goud B, Souchet M, Calmels TP, Mornon JP and Callebaut I: uDENN, DENN, and dDENN: indissociable domains in Rab and MAP kinases signaling pathways. Biochem Biophys Res Commun. 287:688–695. 2001. View Article : Google Scholar : PubMed/NCBI
14	Pfeffer S: A model for Rab GTPase localization. Biochem Soc Trans. 33:627–630. 2005. View Article : Google Scholar : PubMed/NCBI
15	Subramani D and Alahari SK: Integrin-mediated function of Rab GTPases in cancer progression. Mol Cancer. 9:3122010. View Article : Google Scholar : PubMed/NCBI
16	Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N, Liu J, Smith-McCune K, Lu KH, Fishman D, Gray JW and Mills GB: The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med. 10:1251–1256. 2004. View Article : Google Scholar : PubMed/NCBI
17	Rink J, Ghigo E, Kalaidzidis Y and Zerial M: Rab conversion as a mechanism of progression from early to late endosomes. Cell. 122:735–749. 2005. View Article : Google Scholar : PubMed/NCBI
18	Girard M, Allaire PD, McPherson PS and Blondeau F: Non-stoichiometric relationship between clathrin heavy and light chains revealed by quantitative comparative proteomics of clathrin-coated vesicles from brain and liver. Mol Cell Proteomics. 4:1145–1154. 2005. View Article : Google Scholar
19	Majidi M, Hubbs AE and Lichy JH: Activation of extracellular signal-regulated kinase 2 by a novel Abl-binding protein, ST5. J Biol Chem. 273:16608–16614. 1998. View Article : Google Scholar : PubMed/NCBI
20	Marat AL, Dokainish H and McPherson PS: DENN domain proteins: regulators of Rab GTPases. J Biol Chem. 286:13791–13800. 2011. View Article : Google Scholar : PubMed/NCBI
21	Postel EH, Weiss VH, Beneken J and Kirtane A: Mutational analysis of NM23-H2/NDP kinase identifies the structural domains critical to recognition of a c-myc regulatory element. Proc Natl Acad Sci USA. 93:6892–6897. 1996. View Article : Google Scholar : PubMed/NCBI
22	Ling B, Zheng H, Fu G, Yuan J, Shi T, Chen S, Liu Y, Liu Y, Cao Y, Zheng S, Guo S, Han N, Gao Y, Cheng S and Zhang K: Suppression of non-small cell lung cancer proliferation and tumorigenicity by DENND2D. Lung Cancer. 79:104–110. 2013. View Article : Google Scholar : PubMed/NCBI
23	International Union Against Cancer. TNM Classification of Malignant Tumors. 7th edit. Sobin LH, Gospodarowicz MK and Wittekind C: Wiley-Blackwell; New York: 2009
24	Long MJ, Jiang CQ, Lam TH, Lin JM, Chan YH, Zhang WS, Jin YL, Liu B, Thomas GN and Cheng KK: Alcohol consumption and electrocardiographic left ventricular hypertrophy and mediation by elevated blood pressure in older Chinese men: The Guangzhou Biobank Cohort Study. Alcohol. 47:473–480. 2013. View Article : Google Scholar : PubMed/NCBI
25	Takai D and Jones PA: Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA. 99:3740–3745. 2002. View Article : Google Scholar : PubMed/NCBI
26	Takai D and Jones PA: The CpG island searcher: a new WWW resource. In Silico Biol. 3:235–240. 2003.PubMed/NCBI
27	Kiyohara C, Wakai K, Mikami H, Sido K, Ando M and Ohno Y: Risk modification by CYP1A1 and GSTM1 polymorphisms in the association of environmental tobacco smoke and lung cancer: a case-control study in Japanese nonsmoking women. Int J Cancer. 107:139–144. 2003. View Article : Google Scholar : PubMed/NCBI
28	Mollerup S, Ryberg D, Hewer A, Phillips DH and Haugen A: Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res. 59:3317–3320. 1999.PubMed/NCBI
29	Bloethner S, Mould A, Stark M and Hayward NK: Identification of ARHGEF17, DENND2D, FGFR3, and RB1 mutations in melanoma by inhibition of nonsense-mediated mRNA decay. Genes Chromosomes Cancer. 47:1076–1085. 2008. View Article : Google Scholar : PubMed/NCBI
30	Yoshimura S, Gerondopoulos A, Linford A, Rigden DJ and Barr FA: Family-wide characterization of the DENN domain Rab GDP-GTP exchange factors. J Cell Biol. 191:367–381. 2010. View Article : Google Scholar : PubMed/NCBI
31	Croizet-Berger K, Daumerie C, Couvreur M, Courtoy PJ and van den Hove MF: The endocytic catalysts, Rab5a and Rab7, are tandem regulators ofthyroid hormone production. Proc Natl Acad Sci USA. 99:8277–8282. 2002. View Article : Google Scholar : PubMed/NCBI
32	Cheng KW, Lahad JP, Gray JW and Mills GB: Emerging role of RAB GTPases in cancer and human disease. Cancer Res. 65:2516–2519. 2005. View Article : Google Scholar : PubMed/NCBI
33	Ponnambalam S and Baldwin SA: Constitutive protein secretion from the trans-Golgi network to the plasma membrane. Mol Membr Biol. 20:129–139. 2003. View Article : Google Scholar : PubMed/NCBI
34	Loomis RJ, Holmes DA, Elms A, Solski PA, Der CJ and Su L: Citron kinase, a RhoA effector, enhances HIV-1 virion production by modulating exocytosis. Traffic. 7:1643–1653. 2006. View Article : Google Scholar : PubMed/NCBI
35	Ostrowski M, Carmo NB, Krumeich S, Fanget I, Raposo G, Savina A, Moita CF, Schauer K, Hume AN, Freitas RP, Goud B, Benaroch P, Hacohen N, Fukuda M, Desnos C, Seabra MC, Darchen F, Amigorena S, Moita LF and Thery C: Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol. 12:19–30. 2010. View Article : Google Scholar : PubMed/NCBI
36	Henderson MC and Azorsa DO: The genomic and proteomic content of cancer cell-derived exosomes. Front Oncol. 2:382012. View Article : Google Scholar : PubMed/NCBI